Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ispinesib - Cytokinetics

Drug Profile

Ispinesib - Cytokinetics

Alternative Names: 715992; CK 0238273; Ispinesib mesilate; Ispinesib mesylate; SB-715992; SB-715992-S

Latest Information Update: 08 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytokinetics
  • Class Antineoplastics; Benzamides; Quinazolines; Small molecules
  • Mechanism of Action KIF11 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Breast cancer; Colorectal cancer; Haematological malignancies; Renal cancer; Solid tumours
  • Discontinued Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 26 Apr 2019 Discontinued - Phase-I/II for Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Peru (IV) (NCT00607841)
  • 24 Jun 2018 Biomarkers information updated
  • 20 Jul 2012 The National Cancer Institute, in collaboration with GlaxoSmithKline, completes a phase II trial in Renal cancer in the US (NCT00354250)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top